Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection

Gastroenterology. 2021 Nov;161(5):1705-1708.e2. doi: 10.1053/j.gastro.2021.07.011. Epub 2021 Jul 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / genetics
  • Adenocarcinoma / mortality
  • Adenocarcinoma / surgery*
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics
  • Circulating Tumor DNA / blood*
  • Circulating Tumor DNA / genetics
  • Clinical Decision-Making
  • Disease-Free Survival
  • Endoscopic Mucosal Resection* / adverse effects
  • Endoscopic Mucosal Resection* / mortality
  • Esophageal Neoplasms / blood
  • Esophageal Neoplasms / genetics
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / surgery*
  • Esophagectomy* / adverse effects
  • Esophagectomy* / mortality
  • Humans
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual
  • Precision Medicine*
  • Predictive Value of Tests
  • Reproducibility of Results
  • Retrospective Studies
  • Time Factors
  • Whole Genome Sequencing*

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA

Supplementary concepts

  • Adenocarcinoma Of Esophagus